Stay updated on Nivolumab for IDH Mutant Gliomas Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for IDH Mutant Gliomas Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    0.8%
    Check dated 2025-07-11T07:22:06.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    1.0%
    Check dated 2025-07-04T03:59:42.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The page has removed a citation regarding the genetic basis for clinical response to CTLA-4 blockade in melanoma, which included an erratum reference.
    Difference
    0.4%
    Check dated 2025-06-27T00:36:33.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T19:56:20.000Z thumbnail image
  5. Check
    30 days ago
    No Change Detected
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:24:16.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The page has been updated to include information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a new version revision number. Additionally, a citation for a study on the genetic basis for clinical response to CTLA-4 blockade in melanoma has been removed.
    Difference
    6%
    Check dated 2025-05-29T06:12:29.000Z thumbnail image

Stay in the know with updates to Nivolumab for IDH Mutant Gliomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.